2 assets in Urethra Adenocarcinoma

Therapeutic assets addressing Urethra Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Urethra Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Urethra Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)